Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed <i>Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?</i>
Volume
72
Pagination
E137 - E138
DOI
10.1016/j.eururo.2017.05.025
Journal
EUROPEAN UROLOGY
Issue
ISSN
0302-2838